Results 1 to 10 of about 4,258 (140)

Zanubrutinib for high-risk Waldenström macroglobulinemia with complex karyotype and hyperleukocytosis: A case report and literature review [PDF]

SAGE Open Medical Case Reports
To report the management and outcome of an elderly, high-risk lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patient presenting with severe symptomatic anemia, marked hyperleukocytosis, a complex karyotype, dual MYD88/CXCR4 mutations, and ...
Jiale Chen, Jieyi Zhou, Chengyang Xu, Bo Zheng, Jie He, Rong Li   +5 more
doaj   +2 more sources

Mixed cryoglobulinemia; a rare presentation of Waldenström macroglobulinemia [PDF]

Journal of Nephropathology, 2022
Type II mixed cryoglobulinemia is a systemic disease mediated by immune complexes. Renal involvement is present in almost one third of the cases and the membranoprolifer-ative pattern is the most common histological presentation.
Catarina Isabel Ribeiro, Clara Santos, Clara Almeida, Teresa Melo, David Tente, João Carlos Fernandes   +5 more
doaj   +1 more source

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +1 more source

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

eJHaem, 2022
The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib.
Jorge J. Castillo, Shayna Sarosiek, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon   +7 more
doaj   +1 more source

Bilateral central retinal vein occlusion as an initial presentation of Waldenström macroglobulinemia: a case report

Journal of Medical Case Reports, 2023
Background Waldenström macroglobulinemia is a rare hematological malignancy and is the most common diagnosis in patients with hyperviscosity syndrome.
Suraj Shrestha, Elisha Poddar, Bibhav Bashyal, Aayush Adhikari, Prabin Pathak, Suman Acharya, Surendra Sapkota, Anjan Bhattarai, Samriddha Raj Pant, Anjan Shrestha   +9 more
doaj   +1 more source

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia

Therapeutic Advances in Hematology, 2021
The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand syndrome and can be a major risk of bleeding symptoms in this subgroup of patients with Waldenström macroglobulinemia.
María Poza, Rodrigo Íñiguez, Irene Zamanillo, Sara Redondo, Rafael Alonso, Joaquín Martínez-López, Ana Jiménez-Ubieto   +6 more
doaj   +1 more source

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenström Macroglobulinemia

Blood, 2018
Abstract Although estrogens have been shown to regulate normal B cell proliferation and differentiation, the impact of estrogen receptor (ER) signaling on B cell malignancies, including Waldenström Macroglobulinemia (WM), remains unexplored.
Nicola Amodio, Giada Juli, Eugenio Morelli, Maria Angelica Stamato, Maria Eugenia Gallo Cantafio, Cinzia Federico, Katia Todoerti, Emanuela Altomare, Katia Grillone, Marco Rossi, Michele Cea, Antonino Neri, Mariateresa Fulciniti, Nikhil Munshi, Pierosandro Tagliaferri, Pierfrancesco Tassone   +15 more
openaire   +1 more source

A rare clinical presentation of Waldenström Macroglobulinemia mimicking lung cancer

Respiratory Medicine Case Reports, 2022
Waldenström macroglobulinemia rarely presents as pulmonary symptoms, and even rarer as chylothorax. We present a patient who presented with bilateral pleural effusion and a 30 mm solid lesion in the lung.
Michael RT. Laursen, Shailesh Kolekar, Pradeesh Sivapalan, Paul F. Clementsen, Uffe Bodtger   +4 more
doaj   +1 more source

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients

Blood, 2018
Abstract BACKGROUND: Standard rituximab plus chemotherapy salvage treatment has shown moderate activity in patients with relapsed/refractory Waldenström's macroglobulinemia (RR-WM), with 18-months progression free survival (18-PFS) of about 50%.
Giulia Benevolo, Simone Ferrero, Alessandro Andriani, Anna Castiglione, Anna Baraldi, Carola Boccomini, Maria Giuseppina Cabras, Catello Califano, Federica Cavallo, Annarita Conconi, Luigi Curreli, Daniela Drandi, Gianluca Gaidano, Stefano Felici, Martina Ferrante, Donato Mannina, Michele Merli, Anna Lia Molinari, Pellegrino Musto, Gerardo Musuraca, Francesca Gaia Rossi, Roberto Sartori, Monica Tani, Marzia Varettoni, Umberto Vitolo, Lorella Orsucci   +25 more
openaire   +1 more source

Trombosis de la vena central de la retina (TVCR) bilateral asociada a síndrome de hiperviscosidad en una Macroglobulinemia de Waldenström (MW) - a propósito de un caso

ARS MEDICA Revista de Ciencias Médicas, 2019
Introducción: la Macroglobulinemia de Waldenström (MW) es un tipo raro de linfoma de células B caracterizado por la proliferación de células linfoplasmocíticas que secretan altas cantidades de inmunoglobulinas M (IgM) monoclonales. Puede presentarse con una amplia gama de síntomas, entre ellos los derivados del aumento de la viscosidad plasmática ...
Valentina Teresa Luco López, Camila Fernanda Muñoz López, Felipe Humberto González Monsalve, Álvaro Francisco Araya Araya, Rafael González Salazar   +4 more
openaire   +2 more sources